Arylsulfate A is a genetic modifier of Parkinson’s disease through its interaction with α-synuclein

Takeaway

  • Arylsulfate A (ARSA) plasma levels were elevated in individuals with Parkinson’s disease (PD) but not in those with PD with dementia; cell-based laboratory studies suggested ARSA interacts directly with α-synuclein and ARSA deficiency increased α-synuclein aggregation.

Why this matters

    The biological mechanism behind change in blood ARSA level in individuals with PD is unclear, but this study offers the possibility that plasma levels of ARSA and other lysosomal proteins may be used as a diagnostic tool in PD without or with dementia.